drakky-logo

Bictegravir: A New Generation HIV Integrase Strand Transfer Inhibitor

Bictegravir: A New Generation HIV Integrase Strand Transfer Inhibitor

Introduction

Mechanism of Action

By interfering with the pivotal catalytic activity of the HIV integrase enzyme, Bictegravir poses hindrance to the critical viral replication process. It securely binds to the active site of the integrase, resulting in robust complexes effectively restraining the integration thereof, leading to an effective curb on the viral replication. This unique mode of action introduces a strategic vector to impede viral replication, underscoring Bictegravir's distinctness from other HIV drugs and placing it at the forefront in the crusade against HIV.

Efficacy Studies

Multiple efficacy studies for the second-generation HIV integrase strand transfer inhibitor, Bictegravir, verify its effectiveness in suppressing HIV viral multiplication and lowering viral loads to undetectable parameters in both antiretroviral newbies and seasoned patients. In a controlled study on antiretroviral naive patients, treatment regimens centered around Bictegravir consistently manifested superior rates of virologic suppression within 48 weeks. Most patients recorded an HIV RNA count that fell below the measurable limit. Other studies on patients transitioning to the Bictegravir regimen revealed sustained suppression of the virus, highlighting Bictegravir's strength against developed resistance to other antiretroviral drugs. Thus, Bictegravir, with its robust antiviral capacity, represents an effective addition to the HIV treatment paradigm.

Safety Profile

In the latest generation of HIV integrase strand transfer inhibitors, Bictegravir demonstrates a desirable safety profile as validated by various clinical trials. Its usage reports general side effects like nausea, diarrhea, and headaches, albeit their presence is often transient and of a milder degree. Serious ill-effects are a rarity and their occurrence bears no substantial difference from the control group. Minimal metabolism by cytochrome P450 enzymes grants Bictegravir a diminished likelihood of drug interactions. Further, it showcases no considerable shifts in renal functionality. Neither significant variations in lipid profiles nor body weight are attributed to Bictegravir, reinforcing its tolerability. Considering its favorable safety portfolio, Bictegravir holds promise as an effective treatment option for HIV.

Clinical Applications

Treatment-Naive Patients

On the topic of HIV management, treatment-naive patients refer to those who never embarked on antiretroviral therapy before. Bictegravir, a potent, novel INSTI, has produced noteworthy results in clinical study phases among these patients. Research indicates that recipes including bictegravir produce high levels of virologic suppression and sustainable viral control over time, coupled with an acceptable safety profile and negligible side effects. Debuting as first-line therapy for treatment-naive individuals, Bictegravir presents the convenience of once-daily dosage potentially combining with other antiretroviral medicines. Its efficacy and safety make it a vital addition to the therapeutic options for individuals at the starting line of their HIV therapy.

Treatment-Experienced Patients

Conversely, treatment-experienced patients denote those who have trialed antiretroviral therapy for their HIV infection before. The new generation INSTI, Bictegravir, can be a valuable resource for this group. Clinical results have shown that bictegravir-inclusive regimens success in reducing viral load and enhancing CD4 cell count in treatment-experienced patients. Coupling bictegravir with other antiretroviral agents, such as emtricitabine and tenofovir alafenamide, becomes highly effective in securing virologic control and sustaining it over the long haul. Again, regimens involving bictegravir have a favourable safety track record, featuring minimum drug interferences and rare treatment-related side effects. Thus, it makes bictegravir a worthy treatment alternative for treatment-experienced patients, providing a manageable, well-tolerated regimen capable of efficiently managing their HIV infection.

Bictegravir

Special Populations

The effectiveness and safety of Bictegravir, a novel HIV integrase strand transfer inhibitor, extend across various demographic clusters outside the standard HIV-positive population. Investigating its use among specific populations, for example, patients with renal or hepatic impairments, and older patients have been conducted. Findings indicate that patients with mild or moderate renal impairment could take Bictegravir without adjusting the dose. One should exercise prudence with patients with severe renal impairment as data for this group is minimal. Similarly, Bictegravir can be given to patients with mild to moderate liver impairment without dosage modification. For elderly patients, Bictegravir displays comparable efficiency and safety performance as seen in young adults, however, potential drug interactions and common health conditions related to aging should be factored in. All told, Bictegravir serves as a beneficial treatment alternative for special populations, demanding though a thorough assessment and control to guarantee the best outcomes.

Future Perspectives

The prospect of future developments in the arena of HIV treatment is tantalizing, with numerous pathways being actively probed to augment existing treatment modalities. One groundbreaking stride could be the creation of extended-release versions of Bictegravir, a development that might significantly boost treatment adherence and enhance patient outcomes. Furthermore, studies are currently underway to understand the promising synergy of combination therapies that could target different phases of the HIV lifecycle and potentially result in more potent treatment protocols. A new frontier of research involves exploring innovative means of drug delivery, such as nanoparticle technology or implantable devices, which could ensure prolonged, regulated release of Bictegravir, thus minimizing the necessity for daily medication and enhancing the patient's quality of life. These continuous research and innovation efforts underscore a fervent commitment to persistently amplify the quality of HIV treatment methodologies and optimize patient care.

Bibliography

  1. Maertens, G. N., Engelman, A. N., & Cherepanov, P. (2022). Structure and function of retroviral integrase. Nature Reviews Microbiology, 20(1), 20-34. (https://spiral.imperial.ac.uk/bitstream/10044/1/90396/2/Acceptedversion.pdf)

  2. De Clercq, E., Zhang, Z., Huang, J., Zhang, M., & Li, G. (2023). Biktarvy for the treatment of HIV infection: Progress and prospects. Biochemical Pharmacology, 115862. (https://www.sciencedirect.com/science/article/pii/S0006295223004537)

  3. Sax, P. E., Rockstroh, J. K., Luetkemeyer, A. F., Yazdanpanah, Y., Ward, D., Trottier, B., ... & GS-US-380--4030 Investigators. (2021). Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with human immunodeficiency virus. Clinical Infectious Diseases, 73(2), e485-e493. (https://academic.oup.com/cid/article/73/2/e485/5872016)

  4. Acosta, R. K., Willkom, M., Andreatta, K., Liu, H., Martin, R., Parvangada, A., ... & White, K. L. (2020). Switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) from dolutegravir (DTG)+ F/TAF or DTG+ F/tenofovir disoproxil fumarate (TDF) in the presence of pre-existing NRTI resistance. JAIDS Journal of Acquired Immune Deficiency Syndromes, 85(3), 363-371. (https://www.researchgate.net/profile/Kristen-Andreatta/publication/343157290_Switching_to_BictegravirEmtricitabineTenofovir_Alafenamide_BFTAF_from_Dolutegravir_DTGFTAF_or_DTGFTenofovir_Disoproxil_Fumarate_TDF_in_the_Presence_of_Pre-Existing_NRTI_Resistance/links/6228d7863c53d31ba4b48c55/Switching-to-Bictegravir-Emtricitabine-Tenofovir-Alafenamide-B-F-TAF-from-Dolutegravir-DTG-F-TAF-or-DTG-F-Tenofovir-Disoproxil-Fumarate-TDF-in-the-Presence-of-Pre-Existing-NRTI-Resistance.pdf)

  5. Esser, S., Brunetta, J., Inciarte, A., Levy, I., D'Arminio Monforte, A., Lambert, J. S., ... & Robineau, O. (2023). Twelve‐month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV: Real‐world insights from BICSTaR cohorts. HIV medicine. (https://onlinelibrary.wiley.com/doi/pdf/10.1111/hiv.13593)

  6. Tsai, M. S., Sun, H. Y., Chen, C. P., Lee, C. H., Lee, C. Y., Liu, C. E., ... & Taiwan HIV Study Group. (2023). Switching to coformulated bictegravir, emtricitabine, and tenofovir alafenamide maintained viral suppression in adults with historical virological failures and K65N/R mutation. International Journal of Infectious Diseases, 126, 39-47. (https://www.sciencedirect.com/science/article/pii/S1201971222005975)

  7. Ramgopal, M. N., Castagna, A., Cazanave, C., Diaz-Brito, V., Dretler, R., Oka, S., ... & van Wyk, J. (2023). Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial. The Lancet HIV, 10(9), e566-e577. (https://www.natap.org/2023/HIV/PIIS2352301823001364.pdf)

  8. Squillace, N., Ricci, E., Maggi, P., Taramasso, L., Menzaghi, B., De Socio, G. V., ... & CISAI Study Group. (2023). Real-life safety of emtricitabine/tenofovir alafenamide/bictegravir. PLoS One, 18(8), e0289132. (https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0289132)

  9. Sellem, B., Abdi, B., Lê, M., Tubiana, R., Valantin, M. A., Seang, S., ... & Palich, R. (2023). Intermittent Bictegravir/emtricitabine/tenofovir alafenamide treatment maintains high level of viral suppression in virally suppressed people living with HIV. Journal of Personalized Medicine, 13(4), 583. (https://www.mdpi.com/2075-4426/13/4/583)

  10. Gidari, A., Benedetti, S., Tordi, S., Zoffoli, A., Altobelli, D., Schiaroli, E., ... & Francisci, D. (2023). Bictegravir/Tenofovir Alafenamide/Emtricitabine: A Real-Life Experience in People Living with HIV (PLWH). Infectious Disease Reports, 15(6), 766-777. (https://www.mdpi.com/2036-7449/15/6/69)

  11. Ambrosioni, J., Rojas Liévano, J., Berrocal, L., Inciarte, A., de la Mora, L., González-Cordón, A., ... & Mallolas, J. (2022). Real-life experience with bictegravir/emtricitabine/tenofovir alafenamide in a large reference clinical centre. Journal of Antimicrobial Chemotherapy, 77(4), 1133-1139. (https://www.ub.edu/catedres/sites/default/files/content/file/2023/01/23/15/2022-mallolas_real-life-experience-with-bictegravir-emtricitabine-tenofovir-alafenamide-in-a-large-reference-clinical-centre.pdf)